| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A portion of amino acids 150-200 from the human protein was used as the immunogen for the LGALS3 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
LGALS3 Antibody / Galectin 3 is an antibody targeting LGALS3. Host: Mouse. Monoclonal. Clone: LGALS3/4792. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: LGALS3.
- Immunogen: A portion of amino acids 150-200 from the human protein was used as the immunogen for the LGALS3 antibody..
- Species reactivity: Human.
- Localization: Cytoplasm.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Galectin-3 is a member of the beta-galactosidase-binding lectin family. It is associated with cell growth, adhesion, inflammation, mRNA processing, and apoptosis.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
